Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
DOI: 10.1038/s41591-025-03566-1Author: Ramez N. Eskander et al.Published: 2025-5

Forum › Forums › Available Download: › DOI › Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

DOI: 10.1038/s41591-025-03566-1Author: Ramez N. Eskander et al.Published: 2025-5

Tagged: 

  • This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • April 12, 2026 at 6:18 pm #889
    987544pwpadminXavier
    Keymaster

    Title: Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
    Journal: Nature Medicine
    Authors: Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert S. Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Elizabeth Lokich, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
    Date: 2025-5
    DOI: 10.1038/s41591-025-03566-1
    Source: Springer Science and Business Media LLC
    Source URL: https://doi.org/10.1038/s41591-025-03566-1

  • Author
    Posts
Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.